The Europe Bispecific Antibodies Market would witness market growth of 42.1% CAGR during the forecast period (2023-2030).
The most extensively researched use of bispecific antibodies is in cancer immunotherapy particularly in lung, breast, and colon cancer. A bispecific antibody kills the target tumor cell by binding to both the target and cytotoxic cells simultaneously. Technology-advanced solutions for dual targeting methods within the same molecule include bispecific antibodies. The rapid advancement of this therapeutic discipline has been made possible by the effectiveness of BsAbs in cancer as well as noncancer programs.
Rising rates of chronic illnesses like cancer, autoimmune conditions, and infectious diseases, increasing need for targeted medicines, and developments in antibody engineering capabilities are some of the key drivers driving market expansion. People with chronic diseases and mental health disorders also represent a large share of healthcare spending, according to the Centers for Disease Control and Prevention. BsAbs offer a possible path for focused therapies in various disease areas and customized medicine to treat such illnesses.
In Europe, the mental health of numerous individuals has been hampered by the COVID-19 pandemic, which has also highlighted preexisting issues. According to a survey from the UK government, the number of cases of depression in France grew between 2010 and 2020, and people's anxiety increased at the beginning of each lockdown in the nation. All of these figures demonstrate the need for innovative treatments for these problems as well as the need for more R&D investments. Various government support programs and initiatives by major pharmaceuticals have proceeded in this direction, which will be beneficial for the expansion of the regional market.
The Germany market dominated the Europe Bispecific Antibodies Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,194.1 million by 2030. The UK market is experiencing a CAGR of 40.9% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 43.1% during (2023 - 2030).
Based on Indication, the market is segmented into Cancer, Inflammatory & Autoimmune Disorder and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Bispecific Antibodies Market is Projected to reach USD 80.2 Billion by 2030, at a CAGR of 40.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Cancer
- Inflammatory & Autoimmune Disorder
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Amgen, Inc.
- F.Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Akeso, Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Taisho Pharmaceuticals Holding Co., Ltd.
- Immunocore Holdings plc
- GlaxoSmithKline PLC (GSK)
- Novartis AG
- Allergan PLC (AbbVie, Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Bispecific Antibodies Market, by Indication
1.4.2 Europe Bispecific Antibodies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Trials and Approvals
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
Chapter 4. Europe Bispecific Antibodies Market by Indication
4.1 Europe Cancer Market by Country
4.2 Europe Inflammatory & Autoimmune Disorder Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Bispecific Antibodies Market by Country
5.1 Germany Bispecific Antibodies Market
5.1.1 Germany Bispecific Antibodies Market by Indication
5.2 UK Bispecific Antibodies Market
5.2.1 UK Bispecific Antibodies Market by Indication
5.3 France Bispecific Antibodies Market
5.3.1 France Bispecific Antibodies Market by Indication
5.4 Russia Bispecific Antibodies Market
5.4.1 Russia Bispecific Antibodies Market by Indication
5.5 Spain Bispecific Antibodies Market
5.5.1 Spain Bispecific Antibodies Market by Indication
5.6 Italy Bispecific Antibodies Market
5.6.1 Italy Bispecific Antibodies Market by Indication
5.7 Rest of Europe Bispecific Antibodies Market
5.7.1 Rest of Europe Bispecific Antibodies Market by Indication
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Trials and Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional & Segmental Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 Akeso, Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 Johnson & Johnson (Janssen Global Services, LLC)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental &Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Acquisition and Mergers:
6.6 Taisho Pharmaceuticals Holding Co., Ltd.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Immunocore Holdings plc
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.7.4 Recent strategies and developments:
6.7.4.1 Partnerships, Collaborations, and Agreements:
6.8 GlaxoSmithKline PLC (GSK)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.9 Novartis AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Allergan PLC (AbbVie, Inc.)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 Europe Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 2 Europe Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Bispecific Antibodies Market
TABLE 4 Trials and Approvals – Bispecific Antibodies Market
TABLE 5 Acquisition and Mergers– Bispecific Antibodies Market
TABLE 6 Europe Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 7 Europe Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 8 Europe Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 Europe Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 Europe Inflammatory & Autoimmune Disorder Market by Country, 2019 - 2022, USD Million
TABLE 11 Europe Inflammatory & Autoimmune Disorder Market by Country, 2023 - 2030, USD Million
TABLE 12 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 13 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 14 Europe Bispecific Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 15 Europe Bispecific Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 16 Germany Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 17 Germany Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 18 Germany Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 19 Germany Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 20 UK Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 21 UK Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 22 UK Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 23 UK Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 24 France Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 25 France Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 26 France Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 27 France Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 28 Russia Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 29 Russia Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 30 Russia Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 31 Russia Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 32 Spain Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 33 Spain Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 34 Spain Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 35 Spain Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 36 Italy Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 37 Italy Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 38 Italy Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 39 Italy Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 40 Rest of Europe Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 41 Rest of Europe Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 42 Rest of Europe Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 43 Rest of Europe Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 44 Key Information – Amgen, Inc.
TABLE 45 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 46 Key Information – Pfizer, Inc.
TABLE 47 Key Information – Akeso, Inc.
TABLE 48 Key information –Johnson & Johnson
TABLE 49 key Information – Taisho Pharmaceuticals Holding Co., Ltd.
TABLE 50 Key Information – Immunocore Holdings plc
TABLE 51 Key Information – GlaxoSmithKline PLC
TABLE 52 Key Information – Novartis AG
TABLE 53 Key Information – Allergan PLC
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
FIG 5 Europe Bispecific Antibodies Market share by Indication, 2022
FIG 6 Europe Bispecific Antibodies Market share by Indication, 2030
FIG 7 Europe Bispecific Antibodies Market by Indication, 2019 - 2030, USD Million
FIG 8 Europe Bispecific Antibodies Market share by Country, 2022
FIG 9 Europe Bispecific Antibodies Market share by Country, 2030
FIG 10 Europe Bispecific Antibodies Market by Country, 2019 - 2030, USD Million
FIG 11 Recent strategies and developments: Johnson & Johnson